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There is uncertainty about the relationship between anti-HPA-1a
levels and severity of neonatal alloimmune thrombocytopenia
(NAIT). To investigate this relationship further, the concentration of
anti-HPA-1a in HPA-1b homozygous women was determined, using
a newly developed quantitative ELISA that uses purified anti-HPA-1a
to obtain a standard curve. Seventy-eight samples collected from 22
HPA-1b homozygous pregnant women at various stages of
pregnancy were tested. These included five women who had
delivered babies with severe NAIT. A national HPA-1a antibody
standard (NIBSC 93/710), designated as 1 arbitrary unit/mL
(AU/mL), was used in each ELISA to calibrate the purified anti-HPA-
1a, enabling the presentation of results as AU/mL. Moreover,
selected samples were also assayed by PAK 12 and their reactivity
compared with quantity of antibody. The use of the purified HPA-
1a antibody yielded consistent sigmoid curves, enabling the
measurement of HPA-1a antibody concentration in the test samples.
The antibody concentration was significantly correlated with the
antibody titer in the 78 samples studied (R = 0.54, p < 0.001).
Furthermore, there was a significant correlation between PAK 12
and the quantitative ELISA in a selected number of cases, with or
without NAIT (R = 0.71,n = 10;p < 0.02). On the other hand, there
was no correlation of antibody concentration with NAIT incidence
(R = –0.046). This study indicates that there is no relationship
between anti-HPA-1a concentration and severity of NAIT when
ELISA is used, although the correlation between ELISA and other
methods, such as monoclonal antibody immobilization of platelet
antigens (MAIPA) assay, remains to be determined.
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Neonatal alloimmune thrombocytopenia (NAIT)
occurs when the pregnant woman and her fetus differ
in their platelet glycoprotein (GP) polymorphisms and
the woman develops an antibody to the fetal platelet
antigens. In the Caucasian population, most severe
cases of NAIT occur when the woman and fetus differ
in their HPA-1 phenotype.1–3 About 10 percent of HPA-
1b homozygous women who are pregnant with a fetus
expressing HPA-1a antigens develop antibodies to the
fetal platelets, which leads to NAIT in about 20 percent
of these cases.1–3 This can lead to internal hemorrhage,
of which the most serious form is intracranial
hemorrhage (ICH), which can cause the death or
lifelong morbidity of the baby.4 As NAIT is caused by
the passage of IgG across the placenta, it is reasonable
to assume that a relationship would exist between the
isotype of anti-HPA-1a, its concentration, or both and
the severity of the disease, as has been observed for
HDN.5 However, to date, evidence of the relationship
between HPA-1 antibody titer and the severity of NAIT
has been inconclusive. Most studies have shown that
no such relationship exists,2,6–12 while a few studies
have shown a notable or significant correlation
between the HPA-1a antibody isotype or concentration
and the severity of NAIT.13–16
In a recent nationwide study in Scotland involving
26,506 pregnant women, 8.8 percent (28/327) of
confirmed HPA-1b homozygous women developed
HPA-1a antibody. Of those, eight delivered babies with
NAIT, which in five of them was severe (platelet count
< 50 × 109/L).17 Antibody titers during pregnancy were
monitored by a direct ELISA,18 and no correlation
between antibody titer and severity of NAIT was
observed.
The previously mentioned discrepancy in the
relationship between antibody levels and severity of
NAIT could be due to the analytic methods used,
because these are, in general, qualitative or semi-
quantitative. For example, in ELISA methods, patient
samples are incubated with purified GPIIb/IIIa coated
onto the well,10,18 while in other assays, patient samples
are incubated with intact platelets.19,20 In the
monoclonal antibody immobilization of platelet
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antigens (MAIPA) assay,platelets are incubated with the
patient’s antibodies before they are washed and
incubated with monoclonal antibodies directed against
various GPs. The GP, bound with the patient’s antibody
and respective monoclonal antibody, is then extracted
and tested further to determine the specificity of the
patient’s antibody.20 Recently we developed an ELISA
that enables quantitative measurement of antibody in
patients’ serum.21 The aim of this study was to use this
assay to confirm whether there is a relationship
between the concentration of anti-HPA-1a and severity
of NAIT in the cohort of pregnant women with anti-
HPA-1a in our study.The correlation between the direct




Using immobilized HPA-1a, anti-HPA-1a was
purified from serum containing a high titer (256) of
this antibody; the purified anti-HPA-1 was used to
generate a standard curve in the ELISA as previously
described.21 The quantitative antibody ELISA consisted
of the following steps, all of which were performed at
room temperature.21,22 Seven serial doubling dilutions
of the standard (purified) anti-HPA-1a and up to three
serial dilutions of the test samples were incubated in
HPA-1a–coated wells for 30 minutes. Controls
consisting of the same constituents were incubated in
uncoated wells. After washing, the wells were
incubated with alkaline-phosphatase conjugated anti-
human IgG for 30 minutes. The wells were again
washed and incubated with substrate for 30 minutes.
Stop solution was added and absorbances were
obtained using an ELISA reader (MRXTC; Dynex
Technologies, Chantilly, VA). Specific absorbance was
obtained by subtracting the absorbance in uncoated
wells (i.e., without antigen) from that in wells coated
with antigen. Normal serum was not included in the
test because a study of 94 normal antenatal samples
had yielded a mean absorbance plus two SD of less
than 0.1, indicating no cross-reactivity of normal
samples with coated GPIIb/IIIa.23 All ELISA buffers and
reagents were obtained from Axis-Shield plc, Dundee,
Scotland. The purified anti-HPA-1a was used in the
ELISA at a starting dilution of 1 in 4 (added as one part
anti-HPA-1a and 3 parts buffer) in buffer containing
25% of normal pool plasma, with serial doubling
dilutions to 1 in 256. This gave a sigmoid curve against
the linear section of which test plasma samples could
be measured (see Results section). To obtain universal
results, the purified anti-HPA-1a was calibrated against a
national minimum-potency anti-HPA-1a standard
(NIBSC 93/710) designated as 1 arbitrary unit per mL
(AU/mL).
Test samples
As previously indicated, 28 of 327 HPA-1b women
who consented to our nationwide study were found to
have anti-HPA-1a. Of these women, eight delivered
babies with NAIT, five of whom had severe
thrombocytopenia. At the end of the latter study,
samples from 22 women were additionally tested for
antibody, using the quantitative ELISA; this study
included samples from all five women who had
Fig. 1. Calibration of the standard anti-HPA-1a in each assay using NIBSC
93/710 and determination of the anti-HPA-1a concentration in
the test samples from the calibrated standard (AU/mL).A standard
curve is shown with its associated trendline and corresponding
equation. In each ELISA, NIBSC 93/710 anti-HPA-1a (at 1 AU/mL)
was included at a dilution of 1 in 4 (i.e.,0.25 AU/mL). In this assay,
the latter gave a specific absorbance of 0.23 on the y-axis. Using
the formula y = –0.1128 ln(x) + 0.7511, we could calculate the
corresponding reciprocal dilution of S on the x-axis as follows
(where S = the amount of anti-HPA-1a in the standard in AU/mL):
0.1128 ln(x) = 0.7511 – 0.23 = 0.5211
ln(x) = 0.5211/0.1128 = 4.62
x = 100 (calculated through EXP on Microsoft Excel math/trig),
This indicates that S at 1 in 100 = 0.25 AU/ml, implying that S =
25 AU/mL
With S as 25 AU/mL in this assay, we can then calculate the
amount of anti-HPA-1a in test samples. For example, if a test
sample at a dilution of 1 in 16 gives a specific absorbance value
on the y-axis of 0.25, the corresponding anti-HPA-1a
concentration in that sample is calculated as follows:
0.1128 ln(x) = 0.7511 – 0.25 = 0.5011
ln(x) = 0.5011/0.1128 = 4.44
x = 84.8, indicating that anti-HPA-1a in the test sample at a
dilution of 1 in 16 = 25/84.8 = 0.29 AU/mL; implying that the neat
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delivered babies with severe NAIT. Eight consecutive
ELISAs were performed to measure 78 samples
collected from the 22 women at various stages of
pregnancy. In addition,10 selected samples (at delivery
or postdelivery) were tested using PAK 12 (GTI,
Waukesha, WI) to determine whether the latter
correlated in any way with the ELISA. It is worth
noting that PAK 12 also incorporates GPIIb/IIIa-coated
wells, although the GP is attached to the wells via a
monoclonal antibody and not directly as in our ELISA.
Statistics 
The correlation between the titer or absorbance in
the PAK 12 and the antibody concentration was
calculated using the Pearson product moment
correlation coefficient. The significance in the
difference of antibody quantity between low and high
titer samples was determined using the Wilcoxon t test.
Results
Consistency of the anti-HPA-1a standard
As before,21 consistent sigmoid curves were
obtained by the purified anti-HPA-1a standard in the
ELISA (data not shown). In each assay, the NIBSC
93/710 anti-HPA-1a (designated 1 AU/mL) was assayed
at a 1 in 4 dilution and the amount of antibody in the
purified anti-HPA-1a standard was calculated as shown
in Figure 1. This yielded an average value of 25 AU/mL
for the purified anti-HPA-1a. Such calibration of the
purified anti-HPA-1a in each ELISA enabled
measurement of the test samples in standard
quantitative units (AU/mL).
Amount of antibody in the test samples
Seventy-eight samples obtained from various stages
of pregnancy of 22 women with anti-HPA-1a were
assayed. Thirty-four weakly reactive antibody samples
of titers less than or equal to 2 gave a mean antibody
quantity of 0.58 AU/mL (± 0.42 SD). In contrast, 16
strongly reactive antibody samples with titers between
32 and 256 gave a significantly higher mean antibody
concentration of 4.27 (± 3.44) AU/mL, p < 0.0005.
Overall, the antibody concentration was significantly
correlated with the titer in the 78 samples studied (R =
0.54, p < 0.001) (Fig. 2). Furthermore, there was a
significant correlation between the results of PAK 12
and the quantitative ELISA (Fig. 3). However, no
relationship was found between antibody
concentration and severity of NAIT (R = –0.046).
Indeed, as shown in Figure 4, antibody concentration
barely rose above 1 AU/mL during pregnancy in three
of the five severe NAIT cases (charts B, D, and E;
respective platelet counts are shown in the figure
legend); in contrast, in two cases of normal delivery
platelet counts, appreciably higher concentrations of 4
to 10 AU/mL were observed in the third trimester
(charts H and I). Antibody concentrations of between
1 and 6 AU/mL were observed during pregnancy in the
remaining two severe NAIT cases (charts A and C). The
selected cases (10/22) in Figure 4 highlight the
variability of the relationship between antibody
Fig. 2. The correlation between anti-HPA-1a titer and concentration.
Comparison of the antibody titer (obtained in a previous study
using a direct ELISA) with the antibody concentration obtained
using the quantitative ELISA in this study showed a significant










Fig. 3. The correlation between PAK 12 and the quantitative ELISA. Ten
selected samples, including three severe NAIT cases (arrows),
were tested using the PAK 12 and quantitative ELISA. A
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Fig. 4. Antibody concentration in 10 representative women with anti-HPA-1a during pregnancy.
D = delivery, PN = postnatal. All platelet counts at delivery (× 109/L)
A to E: Severe NAIT. Respective platelet counts: 21, 13, 14, 8, and 42. F: Mild NAIT. Platelet count: 87. G to J: No NAIT.The concentration of antibody
during pregnancy did not appear to be indicative of the severity of NAIT.
C
concentration and severity of NAIT. All five women
who gave birth to babies with severe NAIT were HLA-
DR3*01 positive (data not shown). The thrombocyto-
penia resolved without treatment in one of the babies,
while those of the other four women received one or
two transfusions with HPA-1b homozygous platelets
before their platelet counts returned to normal.17
Discussion
In this study, the relationship between anti-HPA-1a
concentration and severity of NAIT was assessed using
a newly developed quantitative ELISA. During our
nationwide Scottish study we did not find a correlation
between antibody titer and severity of NAIT. Our aim,
therefore,was to determine whether such a correlation
would be observed upon accurate quantitation of
antibody in samples obtained from the same cohort.
Seventy-eight samples collected from 22 antibody-
positive women during pregnancy were tested. A
significant correlation was observed between antibody
titer and concentration (i.e.,between the direct ELISA18
and the quantitative ELISA,21 respectively). Based on
this correlation, it was not surprising that no
relationship was observed in the current study
between antibody concentration and severity of NAIT,
since the latter was not related to antibody titer either.
Our findings are in keeping with those of many
other studies where investigators have failed to find
such a relationship.6–12 In a study by Kaplan et al.,8 one
in five mothers who delivered thrombocytopenic
babies did not have detectable antibodies. A similar
observation was made by Bussel et al.9 in a study of
seven pregnant women who had previously delivered
infants with severe NAIT. Two of these seven women,
whose fetuses developed thrombocytopenia during
the early phase of their subsequent pregnancy, had no
detectable antibody. However, based on their previous
history, IVIG was infused into these women in an
attempt to raise the platelet count of the fetuses before
delivery. Using an ELISA similar to ours, Proulx et al.10
analyzed the sera from 36 mothers who gave birth to
thrombocytopenic babies. Their results indicated that
neither the titer nor the isotype of the antibody could
predict the severity of NAIT. In contrast, Mawas et al.13
found a significant increase of anti-HPA-1a of the IgG3
immunoglobulin class in women who delivered
severely thrombocytopenic babies, although the levels
of IgG1, IgG2, and IgG4 (and overall IgG levels)
remained the same between the two groups. However,
the method they used was a modified MAIPA assay
using HPA-1a homozygous platelets and not ELISA
plates coated with HPA-1a GPIIb/IIIa GP. Likewise, in
two other recent studies where MAIPA assay was used,
a relationship was found between antibody titer and
quantification and severity of NAIT.14–15 In the study in
East Anglia, England, by Williamson et al.,14 a significant
correlation between severity of NAIT and a third
trimester anti-HPA-1a titer of less than 32 was found.
Moreover, in a smaller study by Jaegtvik et al.15 in
Norway, an obvious relationship between antibody
level at the time of delivery and the severity of NAIT
was observed. Nevertheless, two women with barely
detectable antibodies delivered babies with severe
NAIT. In addition, one woman with high antibody
levels delivered a baby with mild NAIT (cord platelet
count of around 125 × 109/L),but this was attributed to
the protective effect of anti-D that was also present in
her serum. In a recent study by Maslanka et al.,16 where
144 of 8013 pregnant women were found to be HPA-1b
homozygous, 12 of 122 of the HPA-1b women
produced anti-HPA-1a (as determined by MAIPA assay);
two of the babies had severe antenatal thrombocyto-
penia and two had mild NAIT. Due to the small number
of cases, no definitive conclusion could be drawn
regarding the relationship of antibody titer to severity
of disease. However, the four thrombocytopenic cases
occurred in mothers who had antibody titers of 4 or
higher, while no thrombocytopenia was observed in
those mothers who had weakly reactive anti-HPA-1a
detectable only after delivery.
Although antibodies to other human platelet
glycoprotein polymorphisms, such as HPA-5b and HPA-
4b, may have mechanisms of action that differ from
those of anti-HPA-1a, it is worth noting that discrep-
ancies have also been noted with such antibodies in
relation to severity of NAIT.24–26 While a study by Kurz
et al.24 did not find HPA-5b antibody titer to be a
predictor of disease, a study by Ohto et al.25 found
significant association between postnatal platelet
concentration (Day 3) and anti-HPA-5b titer in the third
trimester of greater than or equal to 64. In addition, no
relationship between anti-HPA-4b and severity of NAIT
was observed in a large Japanese study.26 (Antibodies
in the latter two studies were determined by means of
a mixed passive hemagglutination assay.)
It is clear that there are no consistent results
illuminating the relationship of anti-HPA-1a concen-
tration and severity of NAIT. The discrepancy between
the various studies could be due to the use of different
assays. It appears that all those who have used ELISA
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incorporating GP-coated wells have failed to find a
correlation between anti-HPA-1a levels and severity of
NAIT, whereas all those who have found such a
relationship have used a MAIPA assay. However, this is
not to say that the use of a MAIPA assay always yields
such a correlation.7,10,11 In this study we calibrated the
purified anti-HPA-1a standard in each assay against
NIBSC 93/710,designated as 1 AU/mL. This enabled the
quantitation of anti-HPA-1a in all of our samples as
AU/mL. Three of five women who had delivered babies
with severe NAIT exhibited consistently low
concentrations of anti-HPA-1a throughout their
pregnancies, barely exceeding 1 AU/mL. Although the
remaining two women in this group exhibited higher
antibody concentrations, the amounts interestingly
declined in the second trimester, rising again in the
third trimester and postdelivery. In contrast, two
women with high, albeit fluctuating, antibody
concentrations from 4 to 10 AU/mL during pregnancy
delivered babies with normal platelet counts. Our
results, therefore, indicate that the antibody
quantification during pregnancy is not a reliable
predictor of severity of NAIT. However, an inverse
relationship between antibody levels and platelet
counts in utero cannot be ruled out, nor can the effect
of variation of maternal blood volume in our cohort of
pregnant women; it is conceivable that some of those
with low antibody levels could have had larger blood
volumes than those with high antibody levels.
Based on the apparent discrepancy between ELISA-
based test systems and MAIPA assays, it would be useful
to carry out a comparison between MAIPA assay and
GPIIb/IIIa-coated quantitative ELISAs using the same
samples. In the meantime, in the absence of a
consensus on the role of anti-HPA-1a concentration in
NAIT, the clinical outcome (antenatal ICH), the degree
of thrombocytopenia (platelet count < 20 × 109/L) in
previously affected pregnancies, or both appear to be
the predictors of the likely severity of fetomaternal
alloimmune thrombocytopenia, though only in
subsequently affected pregnancies.27
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